Literature DB >> 31677603

The Impact of Thyroid Function and TPOAb in the First Trimester on Pregnancy Outcomes: A Retrospective Study in Peking.

Yang Zhang1, Weijie Sun2, Sainan Zhu3, Youyuan Huang1, Yu Huang4, Ying Gao1, Junqing Zhang1, Huixia Yang2, Xiaohui Guo1.   

Abstract

CONTEXT: The impact of mild TSH elevation (2.5-4.08 mIU/L) on pregnancy outcomes is unclear. The treatment strategy for mild TSH elevation is dependent on thyroid peroxidase antibody (TPOAb) status according to the guidelines.
OBJECTIVE: To assess the effects of mild thyroid dysfunction combined with TPOAb status in the first trimester on pregnancy outcomes and the impact of levothyroxine (L-T4) treatment on pregnancy outcomes.
DESIGN: The study retrospectively evaluated 3562 pregnant women. A total of 3296 untreated women were divided into 4 subgroups: group A: 4.08 < TSH <10 mIU/L, TPOAb+/-; group B: 2.5 < TSH ≤ 4.08 mIU/L, TPOAb+; group C: 2.5 < TSH ≤ 4.08 mIU/L, TPOAb-; and group D: 0.23 ≤ TSH ≤ 2.5 mIU/L, TPOAb+/-. The other 266 women with L-T4 treatment were divided into TSH 4.08 to 10 mIU/L and 2.5 to 4.08 mIU/L subgroups.
SETTING: The study was conducted at Peking University First Hospital in China. PATIENTS: A total of 3562 pregnant women were evaluated. MAIN OUTCOME MEASURES: The incidence of pregnancy outcomes in the untreated subgroups (groups A-D) and treated subgroups were measured.
RESULTS: Miscarriage and maternal composite outcome risks were 3.53 (1.85-6.75) and 2.19 (1.26-3.81) times greater in group A; 1.58 (1.17-2.13) and 1.27 (1.04-1.54) times greater in group C than in group D. L-T4 improved the miscarriage risk in the TSH 4.08 to 10 and 2.5 to 4.08 mIU/L groups but doubled the risk of gestational diabetes mellitus in the TSH 2.5 to 4.08 mIU/L treated group compared with the untreated group.
CONCLUSIONS: TSH 2.5 to 4.08 mIU/L combined with TPOAb- during early pregnancy was associated with miscarriages and maternal composite outcomes. The advantages and disadvantages of L-T4 administration in TSH 2.5 to 4.08 mIU/L pregnant women remain uncertain. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  TPOAb; TSH elevation; adverse pregnancy outcomes; intervention

Mesh:

Substances:

Year:  2020        PMID: 31677603     DOI: 10.1210/clinem/dgz167

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  A Predictive Role of Autoantibodies Against the Epitope aa168-183 of ENO1 in the Occurrence of Miscarriage Related to Thyroid Autoimmunity.

Authors:  Xiaoqing He; Yifu Liu; Haoyu Wang; Wei Sun; Yihan Lu; Zhongyan Shan; Weiping Teng; Jing Li
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

2.  Assessing maternal thyroid function and its relationship to duration of the first stage of labor.

Authors:  Hongcheng Wei; Quanquan Guan; Qiurun Yu; Ting Chen; Xu Wang; Yankai Xia
Journal:  Eur Thyroid J       Date:  2022-03-17

3.  Relationship Between Subclinical Hypothyroidism in Pregnancy and Hypertensive Disorder of Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Yue Han; Jun Wang; Xiaoying Wang; Ling Ouyang; Yan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555

4.  Associations between thyroid function and gestational diabetes mellitus in Chinese pregnant women: a retrospective cohort study.

Authors:  Geng-Dong Chen; Xiao-Yan Gou; Ting-Ting Pang; Peng-Sheng Li; Zi-Xing Zhou; Dong-Xin Lin; Da-Zhi Fan; Xiao-Ling Guo; Li-Juan Wang; Zheng-Ping Liu
Journal:  BMC Endocr Disord       Date:  2022-02-21       Impact factor: 2.763

5.  Associations Between Maternal Thyroid Function and Birth Outcomes in Chinese Mother-Child Dyads: A Retrospective Cohort Study.

Authors:  Geng-Dong Chen; Ting-Ting Pang; Xia-Fen Lu; Peng-Sheng Li; Zi-Xing Zhou; Shao-Xin Ye; Jie Yang; Xiu-Yin Shen; Dong-Xin Lin; Da-Zhi Fan; De-Mei Lu; Zheng-Ping Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-05       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.